3CLogic and Glidefast Expand Partnership to Deliver Integrated Contact Center Solutions for ServiceNow®
Two leading industry partners enter into new distribution agreement to deliver combined CRM and CCaaS solutions to ServiceNow ecosystem.
ROCKVILLE, Md., April 8, 2025 /CNW/ -- 3CLogic, the leading AI-powered contact center platform purpose-built for ServiceNow®, today announced an expanded partnership with Glidefast Consulting, an Elite ServiceNow Partner. As part of the new distribution agreement, Glidefast will now act as an official reseller of 3CLogic's AI and Contact Center-as-a-Service (CCaaS) offerings, providing clients with a fully integrated voice solution designed to enhance ServiceNow's CRM and Industry workflows.
The expansion comes as ServiceNow continues to accelerate its focus on front-office transformation, where voice remains a critical channel for customer engagement and service delivery. With this deepened collaboration, 3CLogic and Glidefast are positioned to meet the rising demand for native, scalable voice solutions that unify digital and human interactions across the Now Platform.
"As enterprises double down on delivering seamless service experiences, voice is emerging as a vital component in the ServiceNow ecosystem," said Brett Karl, VP of Partner Solutions & Alliances at GlideFast Consulting. "With our deep technical expertise and proven success across ServiceNow implementations, GlideFast is uniquely positioned to help customers unlock the full value of our integrated voice and workflow solutions."
3CLogic's ServiceNow-certified Contact Center solutions extend the capabilities of the Now Platform by embedding intelligent Voice AI, intelligent call routing, real-time transcriptions, AI-powered speech analytics, and analytics directly into ServiceNow's existing workflows and products. This empowers organizations to streamline operations, remove data silos, lowering operating costs and provide a more unified customer experience.
As an authorized reseller, Glidefast will offer 3CLogic's solutions globally alongside its full suite of ServiceNow services—helping clients accelerate deployment timelines, reduce implementation complexity, and ensure long-term success with their voice strategy.
"We're excited to deepen our partnership with 3CLogic and bring their powerful voice capabilities directly to the ServiceNow community," said Brett. "Together, we're delivering a seamless, next-generation contact center experience that amplifies the power of the Now Platform and transforms how organizations connect with customers."
Both 3CLogic and Glidefast will be sponsors at the ServiceNow's upcoming annual conference, Knowledge 25 where they will be showcasing their latest CX capabilities and services. To learn more about 3CLogic's ServiceNow voice solutions and the expanded partnership, visit www.3clogic.com or contact info@3clogic.com.
About 3CLogic3CLogic transforms customer and employee experiences with its patented and award-winning AI-powered cloud contact center solutions purpose-built to enhance today's leading CRM and Customer Service Management platforms. Globally available and leveraged by the world's leading brands, its offerings empower enterprise organizations with innovative capabilities, such as intelligent self-service, Generative AI, Conversational AI, agent automation & coaching, and AI-powered sentiment analytics — all designed to lower operational costs, maximize ROI, and deliver better, faster, and more personalized interactions for IT, employee, and customer service. For more information, please visit www.3clogic.com.
About GlideFast ConsultingGlideFast Consulting is an Elite ServiceNow Partner and leading provider of ServiceNow solutions for enterprise and public sector clients. Renowned for its deep platform expertise and commitment to customer success, GlideFast helps organizations maximize the value of ServiceNow through strategic advisory, implementation, managed services, and custom application development. With a proven track record across IT, employee, and customer workflows, GlideFast delivers scalable solutions that drive digital transformation, improve operational efficiency, and accelerate time to value.
Recognized as the 2023 and 2024 Customer & Industry Workflows Partner of the Year, GlideFast is also part of ServiceNow's exclusive Delivery Success Program—a distinction awarded to partners with a proven history of delivering exceptional outcomes. With a validated Customer Service Management (CSM) practice, GlideFast brings deep expertise across CRM and retail use cases, helping organizations elevate the customer experience through innovative solutions built on the ServiceNow platform.
As a trusted partner in the ServiceNow ecosystem, GlideFast continues to lead through best-in-class services, integrated partner solutions, and a relentless focus on customer outcomes. For more information, please visit www.glidefast.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/3clogic-and-glidefast-expand-partnership-to-deliver-integrated-contact-center-solutions-for-servicenow-302422145.html
SOURCE 3CLogic
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2025/08/c9415.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
BlackSky Newest Gen-3 Delivers First Very High-Resolution Imagery at Warfighting Speed, 12 Hours Following Launch
Recently collected Gen-3 unit two images have demonstrated the timely operational value of space-based dynamic monitoring in support of strategic and tactical defense and intelligence missions HERNDON, Va., June 10, 2025--(BUSINESS WIRE)--BlackSky Technology Inc. (NYSE: BKSY) has delivered the first very high-resolution images from the company's second Gen-3 satellite just 12 hours following its successful launch last Monday. "In today's national security environment, BlackSky's customers require space-based intelligence that moves at warfighter speed," said Brian O'Toole, BlackSky CEO. "BlackSky's newest Gen-3 satellite has delivered low-latency, very high-resolution imagery on its first day in orbit demonstrating the maturity of our AI-enabled architecture and demonstrates the agile, mission-ready resilience of our commercial capabilities today." Early morning Gen-3, unit two, imagery collected yesterday at 7:45 a.m. China Standard Time over Golmud Air Base, Qinghai Province, China has demonstrated the timely operational value of high-cadence, space-based dynamic monitoring capabilities in support of strategic and tactical surveillance, reconnaissance and tracking defense and intelligence missions. Gen-3 gives decision makers the ability to discern vital aircraft movements, ground vehicle positioning and critical facility operations that can provide valuable real-time context to multisource intelligence efforts. "BlackSky is committed to giving customers an unparalleled operational advantage at disruptive speed, scale and economics. Our real-time dynamic monitoring capabilities offer a strong complement to national space assets, especially in support of time-dominant strategic and tactical operations," said O'Toole. As part of BlackSky's high-cadence, time-diverse constellation, each new Gen-3 satellite is expected to accelerate the development of new customer applications in automated real-time and predictive battlefield monitoring. Gen-3 customers have subscription-based access to high-cadence, time diverse 35-centimeter very high-resolution imagery with AI-enabled automated detection analytics that identify and classify a wide library of vehicles, aircraft, vessels and other objects of military interest. As BlackSky's constellation evolves with the regular addition of Gen-3 satellites, BlackSky will continue to optimize for increased constellation capacity and flexibility giving customers confidence in reliable access to services. About BlackSky BlackSky is a real-time, space-based intelligence company that delivers on-demand, high frequency imagery, analytics, and high-frequency monitoring of the most critical and strategic locations, economic assets, and events in the world. BlackSky owns and operates one of the industry's most advanced, purpose-built commercial, real-time intelligence systems that combines the power of the BlackSky Spectra® tasking and analytics software platform and our proprietary low earth orbit satellite constellation. With BlackSky, customers can see, understand and anticipate changes for a decisive strategic advantage at the tactical edge, and act not just fast, but first. BlackSky is trusted by some of the most demanding U.S. and international government agencies, commercial businesses, and organizations around the world. BlackSky is headquartered in Herndon, VA, and is publicly traded on the New York Stock Exchange as BKSY. To learn more, visit and follow us on X. Forward-Looking Statements Certain statements in this press release may contain forward-looking statements within the meaning of the federal securities laws with respect to BlackSky. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, forward-looking statements reflect our expectations, plans, or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause their assessments to change. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed in BlackSky's disclosure materials filed from time to time with the SEC which are available at the SEC's website at or on BlackSky's Investor Relations website at View source version on Contacts Investor Contact Aly BonillaVP, Investor Relationsabonilla@ Media Contact Pauly CabellonSr. Director, External Communicationsbksypr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 'Company,' 'we,' 'us,' or 'our') within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Without limiting the foregoing, we may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'forecast,' 'guidance,' 'outlook,' 'may,' 'can,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ('FDA') approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ('EMA') approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS InvestorsIR@ ext. 150 MediaPR@ 650-260-7120 ext. 150Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Grand Opening Celebrates Little Patuxent Senior Apartments in Gambrills
GAMBRILLS, Md., June 10, 2025 /PRNewswire/ -- Green Street Housing, HRH Holdings, and Good Works will host a ribbon–cutting ceremony on Wednesday, June 11, 2025, at 11:30 AM to mark the grand opening of Little Patuxent Senior Apartments, a 78–unit affordable senior community at 1074 Crain Highway, Gambrills. Anne Arundel County Council Members Julie Hummer and Allison Pickard will join project partners and community leaders for the celebration. Little Patuxent Senior is a four–story, elevator–served building offering one– and two–bedroom apartments for residents aged 62 and older earning 30–60 percent of area median income. The community is steps from shopping, dining, and essential services and features a fitness center, community room, library, business center, walking trail with fitness stations, bocce court, and outdoor picnic areas. A newly opened Slim Chickens restaurant on the site will cater lunch for attendees. The development was financed with Low–Income Housing Tax Credits from The Richman Group, bonds and Rental Housing Works funds from the Maryland Department of Housing and Community Development, and a HOME loan from Arundel Community Development Services. "Little Patuxent Senior Apartments in Anne Arundel County is the latest example of what Green Street Housing can achieve through strong public–private partnerships—delivering 78 new affordable homes for seniors and building on our record of expanding housing opportunities across Maryland," said Tom Ayd, CEO of Green Street Housing. "We're proud to celebrate this milestone and look forward to welcoming residents home, confident it will spur similar efforts in other communities." "Little Patuxent moved from contract to completion in five years—four spent on financing and entitlements, one on construction. My hope is that policymakers recognize how efficiently teams like ours can deliver when the path is clear and take steps to expand funding and reduce entitlement friction so we can bring more affordable homes to Maryland faster," said Tim Hoerner IV, Principal, HRH Holdings. Leasing Information – Little Patuxent Senior Apartments is now open and actively leasing move–in–ready homes. Prospective residents and their families can explore floorplans, photos, and a 360–degree virtual tour at or schedule a private visit by calling (240) 868–6645. The community is professionally managed by TM Management, providing responsive on–site service and resident programs. Designed with savings and convenience in mind, each residence features ENERGY STAR® appliances and in–home washers and dryers, while an on–site bus stop connects residents to nearby medical centers and shopping, supporting independence for those who prefer not to drive. The event is open to the public, including seniors, their families, media, elected officials, and community stakeholders. After the ribbon cutting, guests may take brief guided tours of the apartments and amenities and enjoy a Slim Chickens–catered lunch. On–site parking is available. About Green Street HousingGreen Street Housing is a Maryland–based affordable–housing developer with over 25 years of experience and hundreds of millions of dollars in closed transactions across the Mid–Atlantic. The company integrates ENERGY STAR practices and on–site solar energy in all of its Maryland communities. Learn more at About HRH HoldingsFounded in 2019 and headquartered in Annapolis, HRH Holdings specializes in land entitlement, site development, and commercial leasing, with a growing focus on affordable housing in Anne Arundel County. About Good WorksGood Works has developed more than 700 affordable family and senior rental units over the past 25 years and remains dedicated to strengthening communities through high–quality, affordable housing. Contact: Dave Layfield Phone: 443-523-6265 Email: 396427@ View original content to download multimedia: SOURCE Green Street Housing
